| Danai Khemasuwan, MD | |
|
77 Warren St Fl 2, Brighton, MA 02135-3601 | |
| (617) 789-2545 | |
| (617) 779-6798 |
| Full Name | Danai Khemasuwan |
|---|---|
| Gender | Male |
| Speciality | Critical Care (intensivists) |
| Experience | 20 Years |
| Location | 77 Warren St Fl 2, Brighton, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1912104860 | NPI | - | NPPES |
| 273373 | Other | MA | MA LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 9396470-1205 (Utah) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Medical College Of Virginia Hospitals | Richmond, VA | Hospital |
| Henrico Doctors' Hospital | Richmond, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Intensive Care Consortium Inc | 0244269413 | 370 |
| Mcv Associated Physicians | 4385542117 | 1312 |
News Archive
Speaking at a briefing on Thursday sponsored by the Kaiser Family Foundation (KFF) and the Department of Health and Human Services (HHS) to explore the department's role in global health and its Global Health Strategy, HHS Secretary Kathleen Sebelius discussed the agency's "first global health strategy ..., which explains the Obama administration's priorities during an era of budget-cutting," CQ HealthBeat reports.
Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today will present Phase 3 results that showed osteoarthritis (OA) patients treated with investigational SoluMatrix meloxicam 5 mg and 10 mg, a low dose nonsteroidal anti-inflammatory drug (NSAID), reported significantly greater pain relief compared with placebo.
MooDFOOD, the largest randomized clinical trial to study the effects of nutritional strategies on the prevention of major depressive disorder concludes that daily intake of nutritional supplements cannot prevent depression.
City of Hope researchers received approval from the U.S. Food and Drug Administration (FDA) to conduct the first-in-human study of a neural stem cell-based therapy targeting recurrent high-grade gliomas, the most aggressive type of brain tumor. Karen S. Aboody, M.D., associate professor in City of Hope's Department of Neurosciences, leads the research team that developed this treatment strategy. Jana Portnow, M.D., assistant professor and assistant director of the Brain Tumor Program at City of Hope, is the principal investigator for the clinical trial.
REMIND-A-CAP a novel product created to help address the $200 billion challenge of medication non-adherence in the United States, was awarded the top Innovative Branded Technology honor in the recently announced 2014 PM360 Pharma Choice Awards. The customizable and patented pill bottle cap with an ergonomic dial to set for next dosing provides a much-needed tool for companies and brands looking to improve their patient to product adherence.
› Verified 3 days ago
| Entity Name | Mcv Associated Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710959457 PECOS PAC ID: 4385542117 Enrollment ID: O20031230000559 |
News Archive
Speaking at a briefing on Thursday sponsored by the Kaiser Family Foundation (KFF) and the Department of Health and Human Services (HHS) to explore the department's role in global health and its Global Health Strategy, HHS Secretary Kathleen Sebelius discussed the agency's "first global health strategy ..., which explains the Obama administration's priorities during an era of budget-cutting," CQ HealthBeat reports.
Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today will present Phase 3 results that showed osteoarthritis (OA) patients treated with investigational SoluMatrix meloxicam 5 mg and 10 mg, a low dose nonsteroidal anti-inflammatory drug (NSAID), reported significantly greater pain relief compared with placebo.
MooDFOOD, the largest randomized clinical trial to study the effects of nutritional strategies on the prevention of major depressive disorder concludes that daily intake of nutritional supplements cannot prevent depression.
City of Hope researchers received approval from the U.S. Food and Drug Administration (FDA) to conduct the first-in-human study of a neural stem cell-based therapy targeting recurrent high-grade gliomas, the most aggressive type of brain tumor. Karen S. Aboody, M.D., associate professor in City of Hope's Department of Neurosciences, leads the research team that developed this treatment strategy. Jana Portnow, M.D., assistant professor and assistant director of the Brain Tumor Program at City of Hope, is the principal investigator for the clinical trial.
REMIND-A-CAP a novel product created to help address the $200 billion challenge of medication non-adherence in the United States, was awarded the top Innovative Branded Technology honor in the recently announced 2014 PM360 Pharma Choice Awards. The customizable and patented pill bottle cap with an ergonomic dial to set for next dosing provides a much-needed tool for companies and brands looking to improve their patient to product adherence.
› Verified 3 days ago
| Entity Name | Intensive Care Consortium Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629019062 PECOS PAC ID: 0244269413 Enrollment ID: O20131024001493 |
News Archive
Speaking at a briefing on Thursday sponsored by the Kaiser Family Foundation (KFF) and the Department of Health and Human Services (HHS) to explore the department's role in global health and its Global Health Strategy, HHS Secretary Kathleen Sebelius discussed the agency's "first global health strategy ..., which explains the Obama administration's priorities during an era of budget-cutting," CQ HealthBeat reports.
Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today will present Phase 3 results that showed osteoarthritis (OA) patients treated with investigational SoluMatrix meloxicam 5 mg and 10 mg, a low dose nonsteroidal anti-inflammatory drug (NSAID), reported significantly greater pain relief compared with placebo.
MooDFOOD, the largest randomized clinical trial to study the effects of nutritional strategies on the prevention of major depressive disorder concludes that daily intake of nutritional supplements cannot prevent depression.
City of Hope researchers received approval from the U.S. Food and Drug Administration (FDA) to conduct the first-in-human study of a neural stem cell-based therapy targeting recurrent high-grade gliomas, the most aggressive type of brain tumor. Karen S. Aboody, M.D., associate professor in City of Hope's Department of Neurosciences, leads the research team that developed this treatment strategy. Jana Portnow, M.D., assistant professor and assistant director of the Brain Tumor Program at City of Hope, is the principal investigator for the clinical trial.
REMIND-A-CAP a novel product created to help address the $200 billion challenge of medication non-adherence in the United States, was awarded the top Innovative Branded Technology honor in the recently announced 2014 PM360 Pharma Choice Awards. The customizable and patented pill bottle cap with an ergonomic dial to set for next dosing provides a much-needed tool for companies and brands looking to improve their patient to product adherence.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Danai Khemasuwan, MD 77 Warren St Fl 2, Brighton, MA 02135-3601 Ph: (617) 789-2545 | Danai Khemasuwan, MD 77 Warren St Fl 2, Brighton, MA 02135-3601 Ph: (617) 789-2545 |
News Archive
Speaking at a briefing on Thursday sponsored by the Kaiser Family Foundation (KFF) and the Department of Health and Human Services (HHS) to explore the department's role in global health and its Global Health Strategy, HHS Secretary Kathleen Sebelius discussed the agency's "first global health strategy ..., which explains the Obama administration's priorities during an era of budget-cutting," CQ HealthBeat reports.
Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today will present Phase 3 results that showed osteoarthritis (OA) patients treated with investigational SoluMatrix meloxicam 5 mg and 10 mg, a low dose nonsteroidal anti-inflammatory drug (NSAID), reported significantly greater pain relief compared with placebo.
MooDFOOD, the largest randomized clinical trial to study the effects of nutritional strategies on the prevention of major depressive disorder concludes that daily intake of nutritional supplements cannot prevent depression.
City of Hope researchers received approval from the U.S. Food and Drug Administration (FDA) to conduct the first-in-human study of a neural stem cell-based therapy targeting recurrent high-grade gliomas, the most aggressive type of brain tumor. Karen S. Aboody, M.D., associate professor in City of Hope's Department of Neurosciences, leads the research team that developed this treatment strategy. Jana Portnow, M.D., assistant professor and assistant director of the Brain Tumor Program at City of Hope, is the principal investigator for the clinical trial.
REMIND-A-CAP a novel product created to help address the $200 billion challenge of medication non-adherence in the United States, was awarded the top Innovative Branded Technology honor in the recently announced 2014 PM360 Pharma Choice Awards. The customizable and patented pill bottle cap with an ergonomic dial to set for next dosing provides a much-needed tool for companies and brands looking to improve their patient to product adherence.
› Verified 3 days ago
Dr. Mahendra Carpen, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 736 Cambridge St, Dept. Of Cardiology, Brighton, MA 02135 Phone: 617-789-5151 | |
Syed Kashif Mahmood, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 11 Nevins St Ste 406, Brighton, MA 02135 Phone: 617-562-5432 Fax: 617-789-5049 | |
Brian Ash, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 736 Cambridge St, Mob 505, Brighton, MA 02135 Phone: 617-782-5316 | |
Mikhail Mayskiy, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 736 Cambridge St, Ccp4c, Brighton, MA 02135 Phone: 617-789-2060 Fax: 617-789-5029 | |
Lawrence A. Kenney, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 736 Cambridge St, Seton Pavillion, 3rd Floor, Brighton, MA 02135 Phone: 617-789-2548 Fax: 617-562-7756 | |
Nikolay Korchemny, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 736 Cambridge Street, Office Of Gme, Brighton, MA 02135 Phone: 617-789-2386 | |
Harry Dinerman, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 736 Cambridge St, Mmr 3 Iiem/one, Brighton, MA 02135 Phone: 617-789-3081 Fax: 617-789-3349 |